Skip to main content

Microfat & Nanofat Grafting (GSM / Vulvar Atrophy / Lichen Sclerosus)

Microfat and nanofat grafting is an autologous regenerative-medicine approach using mechanically processed adipose tissue to treat genitourinary syndrome of menopause (GSM), vulvovaginal atrophy, and vulvar dystrophies including lichen sclerosus (VLS). The technique exploits both the volumizing properties of microfat and the regenerative / trophic properties of nanofat (rich in adipose-derived stem cells and growth factors) to attempt reversal of atrophic changes — distinct from filler-style HA, which is volumizing but not regenerative, and distinct from topical estrogen, which palliates without reversing atrophy.[1][2][3] For positioning vs other female cosmetic options see Cosmetic Genital Surgery — Female.

Therapeutic vs cosmetic context

Microfat / nanofat grafting for GSM, vulvovaginal atrophy, or lichen sclerosus refractory to topical steroids is a therapeutic indication with a small but maturing evidence base — distinct from purely cosmetic applications. ACOG 2020 Committee Opinion No. 795 classifies cosmetic genital procedures as not medically indicated, with safety and effectiveness not established; FIGO 2025 echoes this for cosmetic indications. The therapeutic indications above are not what those positions target. Counsel patients clearly on the therapeutic-vs-cosmetic distinction and document the indication.[4]

Critical safety: rare but reported case of severe pulmonary fat embolism after vaginal fat grafting (Wang 2020) — anatomical knowledge and careful technique are mandatory.[5]

Background — GSM and the limits of standard therapy​

GSM affects the majority of peri- and postmenopausal women and includes vaginal dryness, burning, itching, dyspareunia, urinary urgency / frequency, and recurrent UTIs — driven by estrogen deficiency and progressive vulvovaginal atrophy.[1][6] Standard treatments (topical estrogen, DHEA, ospemifene, moisturizers) are effective but require ongoing therapy to maintain benefit and cannot reverse the underlying atrophic process.[6][7] This limitation has driven interest in regenerative approaches that may provide longer-lasting tissue restoration.[7]

Definitions — macrofat vs microfat vs nanofat​

Fat typeParticle sizeHarvestingProcessingPrimary function
Macrofat> 2 mmStandard liposuction cannulaMinimalVolume restoration (large defects)[1][2]
Microfat~ 100–120 µmSmall multiport cannula (1–2 mm holes)Centrifugation or decantingVolume restoration + moderate regeneration[1][3][8]
NanofatSubmicron (no viable adipocytes)Derived from microfatMechanical emulsification + filtrationTissue regeneration (no volumizing)[1][9]

Microfat uses a multiport cannula with small (0.8–1 mm) side holes, retaining intact adipocytes and providing both volume and regenerative capacity.[8][9]

Nanofat was first described by Tonnard et al. 2013 — produced by mechanical emulsification (vigorous back-and-forth between two syringes via a Luer-lock connector, typically 30 passes) followed by filtration through a nylon mesh. The process destroys all viable adipocytes but preserves abundant adipose-derived stem cells (ADSCs), stromal vascular fraction (SVF) cells, growth factors, and extracellular matrix components. The resulting fluid emulsion can be delivered through fine needles (up to 27-gauge).[9]

Biological rationale and mechanism​

The therapeutic effects extend beyond simple volume replacement:

  • ADSCs. Nanofat contains abundant ADSCs with proliferation and differentiation capacity equivalent to unprocessed fat; multilineage differentiation (adipocyte / osteocyte / chondrocyte) plus highly pluripotent MUSE cells.[9][10]
  • Proteomic profile. Mechanical emulsification of microfat into nanofat upregulates pathways involved in innate immunity, coagulation, wound healing, and antimicrobial defense.[11]
  • Lipidomic profile. Nanofat is enriched in anti-inflammatory, antifibrotic, and antimelanogenic lipid mediators (prostacyclin, coumaric acids) vs microfat.[12]

Histologic effects in vulvovaginal tissue (Lai 2023; Casarotti 2018):[13][3]

  • Neocollagenesis — increased collagen production
  • Neoangiogenesis — new blood-vessel formation
  • Increased estrogen-receptor expression — enhanced local hormonal responsiveness
  • Decreased PGP 9.5 (neuropathic-pain marker)
  • Glycogen production, epithelial regeneration, and restoration of lactobacilli colonization with normalization of vaginal pH (sustained at 36 mo)

Surgical technique​

1. Fat harvesting​

  • Donor sites: abdomen, medial thighs, flanks. No significant difference in fat-cell viability between sites.[1][14]
  • Multiport cannula with small side holes for microfat.[1][14]
  • Local or general anesthesia.

2. Fat processing​

StepDetail
MicrofatCentrifugation typically 3 min at 3,000 rpm, or decanting, to separate fat from aqueous and oil fractions.[14][8]
NanofatMicrofat is mechanically emulsified by passing between two syringes (~ 30 times) and then filtered through nylon mesh. The result is a homogeneous, fluid emulsion.[9]
PRP enrichmentSome protocols add PRP to nanofat to enhance regenerative effects.[14][15]

3. Injection​

Menkes 2021 protocol (the landmark vulvovaginal series):[1]

  • Microfat → labia majora (volume restoration of atrophic / deflated labia majora).
  • Nanofat → vaginal mucosa (submucosal) (tissue regeneration).

Lai 2023 MAFT technique injected an average of 21.9 mL into the vagina and 20.8 mL into the vulva and mons pubis.[13]

Procedure performed under local anesthesia ± sedation as an outpatient procedure.

Clinical evidence​

GSM / vulvovaginal atrophy​

StudynTechniqueFollow-upKey outcomes
Menkes 2021[1]50Microfat (labia) + nanofat (vagina)18 moVHI + FSD significantly improved (p < 0.0001); 80% normalized at 6 mo; stable at 18 mo; particular benefit for dryness and dyspareunia
Casarotti & Tremolada 2020[16]35MFAT (vulvar injection)36 mo99% complete symptom resolution at 9–12 mo; no relapse at 3 years; single injection
Casarotti 2018[3]3MFAT (Lipogems®)36 moComplete symptom resolution at 9 mo; histology — glycogen production, vascular hyperplasia, epithelial regeneration, lactobacilli restoration
Lai 2023 MAFT[13]20MAFT (vulvovaginal)6 moFSFI 43.8 → 68.6 (p < 0.001); histologic neocollagenesis + neoangiogenesis + ER expression
Mantovani 2022[17]12MFAT (SEFFIGYN™)5 moAll symptoms significantly improved (p = 0.001–0.008); all patients resumed sexual life

The Moccia 2023 SR of injection treatments for VVA found that microfat + nanofat + PRP led to significant improvement on VHI and FSDS-R, but MFAT alone did not reach significance on validated questionnaires in the studies assessed.[18]

Vulvar lichen sclerosus (VLS) — refractory to topical steroids​

Nanofat grafting has emerged as a promising second-line option for VLS refractory to topical corticosteroids:

  • Gutierrez-Ontalvilla 2022 — RCT n = 20: nanofat + PRP (2 infiltrations 3 months apart) vs topical corticosteroids. Treatment group: significant improvement in symptoms (itching, pain, burning, dyspareunia) and clinical signs (erosions, fissures, stenosis); decreased inflammatory infiltration on biopsy. No improvement in vulvar skin elasticity.[15]
  • Gutierrez-Ontalvilla 2025 Lichen-SVF protocol — single injection of nanofat (40 mL) + SVF (2–3 mL) in n = 18 with moderate-to-severe VLS. At 12 mo: significant reductions in symptom severity (CSS 20.12 → 4.71, p = 0.0025), itching (5D 6.82 → 2.35, p = 0.0136), and QoL improvement. Histology: reduced stromal hyalinization (p = 0.0036), decreased CD3+ T-cell infiltration (p = 0.0068), increased microvascular density (p = 0.0121). Framed as complementary to topical-steroid therapy, not a replacement.[19]
  • Tedesco 2020 RCT n = 40 LS: AD-SVF vs AD-SVF + PRP. Both safe and effective. Combinatory therapy more effective in early-stage patients; discouraged in late-stage disease.[20]

Duration of effect — a defining advantage​

The most striking feature compared to other vaginal-injection treatments is durability:

  • 18 mo — stable in all patients with further FSD improvement between 12 and 18 mo (Menkes 2021).[1]
  • 36 mo — 99% maintained complete symptom resolution with no relapse after a single injection (Casarotti 2020). Histology at 36 mo confirmed sustained tissue regeneration.[16][3]

This long-lasting effect is attributed to the regenerative mechanism (tissue remodeling, neovascularization, stem-cell engraftment) rather than a simple filler effect, distinguishing it from HA-based approaches that require repeat injections every 9–12 mo.[16][3]

Comparison with other vaginal-injection treatments for GSM​

AgentMechanismVolume effectRegenerative effectDurationSessions
Microfat + nanofatVolume + ADSC-mediated regenerationYes (microfat)Strong (nanofat)Up to 36 moUsually single[1][16]
Cross-linked HAVolume + mild tissue stimulationYesModerate (collagen mRNA upregulation)9–12 moRepeat[18]
PRPGrowth-factor-mediated regenerationNoModerateVariableMultiple[18]
MFAT (Lipogems®)Volume + regenerationModerateStrongUp to 36 moSingle[16][3]
CollagenVolume + analgesicMildMild3–6 moMultiple[21]

Complications and safety​

Generally favorable. No major side effects in the published GSM / VLS series.[1][13][19]

Minor complications (common)​

  • Ecchymosis at donor and recipient sites
  • Transient tenderness and swelling
  • Mild pain at injection sites[22]

Potential serious complications (rare but consequential)​

  • Fat embolism (most serious). Wang 2020 case report of severe pulmonary fat embolism after vaginal fat grafting — fat presumably injected directly into perivaginal vessels. The most critical safety concern; underscores the importance of anatomical knowledge and careful injection technique.[5]
  • GRAFT registry (n = 7,052 fat-grafting procedures across all body sites): overall complication rate 5.01%; rates of palpable mass, infection, granuloma, oil cyst all low.[23]
  • Vascular embolism is the principal serious risk of vaginal-wall injection and must be actively prevented.[24]
  • No infections, fat cysts, granulomas, or lipoma formation reported in the nanofat-specific vulvovaginal series.[1][13][9]

Advantages and limitations​

Advantages

  • Autologous material — no allergic / foreign-body reactions.
  • Dual mechanism: volume restoration (microfat) + tissue regeneration (nanofat).
  • Long-lasting results (up to 3 years documented) with a single treatment session.
  • Histologically confirmed reversal of atrophic changes — not just symptom palliation.
  • Applicable to both GSM and refractory VLS.

Limitations

  • Requires a donor-site procedure (liposuction) — additional surgical complexity and morbidity.
  • Not suitable for patients with very low body fat.
  • Evidence base is observational studies and small case series (Level III–IV); no large RCTs specifically for GSM.
  • Variable fat-graft survival; unpredictable resorption.
  • Risk of fat embolism, although extremely rare.[5]
  • Lack of standardized protocols — volumes, processing methods, and injection sites vary across studies.
  • ACOG 2020 and FIGO 2025 classify cosmetic genital procedures as not medically indicated. The GSM / VLS-refractory therapeutic context is distinct, but counseling must clearly distinguish.[4]

Emerging directions​

  • SVF-enriched nanofat (Lichen-SVF protocol) for VLS with histologically confirmed anti-inflammatory and regenerative effects.[19]
  • Nanofat + PRP combinations for early-stage VLS.[15][20]
  • Proteomic and lipidomic profiling of nanofat to identify specific bioactive mediators responsible for regenerative effects.[11][12]
  • ADSC-enriched nanofat with higher pluripotent (MUSE) stem-cell content.[10]

Key takeaways​

  • Microfat / nanofat grafting may reverse the underlying atrophic process in GSM, vulvovaginal atrophy, and refractory VLS — a fundamentally different mechanism from HA / topical estrogen / topical steroids.[1][3][19]
  • Longest follow-up data (36 mo) suggest durable single-session results with histologic evidence of tissue regeneration including neocollagenesis, neoangiogenesis, and restoration of vaginal flora.[16][3]
  • Therapeutic vs cosmetic distinction matters — the strongest evidence is for GSM and VLS-refractory disease, not for cosmetic enhancement in healthy women. Document indication accordingly.
  • Evidence remains small observational studies; fat embolism is the dominant safety concern despite its rarity.[5]
  • Larger RCTs are needed to standardize protocols and confirm long-term safety.

Postoperative management​

  • Activity restriction. Avoid intercourse, tampon use, and strenuous exercise for 2–4 weeks; protect donor site per general lipofilling protocol.
  • Donor-site care. Compression at donor site; avoid pressure on recipient site so as not to compress the graft.
  • Wound care. Ice 48–72 h; loose-fitting clothing; antibiotic ointment to donor incisions.
  • Follow-up. 1 week, 6 weeks, 6 months, 12 months, with VHI / FSFI / FSD as relevant; some series have extended to 18–36 months.
  • Counseling on durability. Counsel that regenerative effects may continue to emerge between 6 and 18 months — early follow-up does not capture the full effect.

See Also​

References​

1. Menkes S, SidAhmed-Mezi M, Meningaud JP, et al. Microfat and nanofat grafting in genital rejuvenation. Aesthet Surg J. 2021;41(9):1060–1067. doi:10.1093/asj/sjaa118

2. Ding P, Lu E, Li G, et al. Research progress on preparation, mechanism, and clinical application of nanofat. J Burn Care Res. 2022;43(5):1140–1144. doi:10.1093/jbcr/irab250

3. Casarotti GA, Chiodera P, Tremolada C. Menopause: new frontiers in the treatment of urogenital atrophy. Eur Rev Med Pharmacol Sci. 2018;22(2):567–574. doi:10.26355/eurrev_201801_14211

4. Committee on Gynecologic Practice, American College of Obstetricians and Gynecologists. Elective female genital cosmetic surgery: ACOG Committee Opinion No. 795. Obstet Gynecol. 2020;135(1):e36–e42. doi:10.1097/AOG.0000000000003616

5. Wang C, Wang X, Huang J, Yu N, Long X. Severe fat embolism after autologous fat grafting in vaginal tightening and breast augmentation surgery. J Int Med Res. 2020;48(8):300060520949109. doi:10.1177/0300060520949109

6. Capito L, Antsaklis A, Gupte S. FIGO Statement: cosmetic genital surgery. Int J Gynaecol Obstet. 2025;170(1):11–14. doi:10.1002/ijgo.70203

7. Kamat P, Frueh FS, McLuckie M, et al. Adipose tissue and the vascularization of biomaterials: stem cells, microvascular fragments and nanofat — a review. Cytotherapy. 2020;22(8):400–411. doi:10.1016/j.jcyt.2020.03.433

8. Yang Z, Jin S, He Y, et al. Comparison of microfat, nanofat, and extracellular matrix/stromal vascular fraction gel for skin rejuvenation: basic research and clinical applications. Aesthet Surg J. 2021;41(11):NP1557–NP1570. doi:10.1093/asj/sjab033

9. Tonnard P, Verpaele A, Peeters G, et al. Nanofat grafting: basic research and clinical applications. Plast Reconstr Surg. 2013;132(4):1017–1026. doi:10.1097/PRS.0b013e31829fe1b0

10. Quintero Sierra LA, Biswas R, Conti A, et al. Highly pluripotent adipose-derived stem cell-enriched nanofat: a novel translational system in stem cell therapy. Cell Transplant. 2023;32:9636897231175968. doi:10.1177/09636897231175968

11. Sanchez-Macedo N, McLuckie M, Grünherz L, Lindenblatt N. Protein profiling of mechanically processed lipoaspirates: discovering wound healing and antifibrotic biomarkers in nanofat. Plast Reconstr Surg. 2022;150(2):341e–354e. doi:10.1097/PRS.0000000000009345

12. Grünherz L, Kollarik S, Sanchez-Macedo N, McLuckie M, Lindenblatt N. Lipidomic analysis of microfat and nanofat reveals different lipid mediator compositions. Plast Reconstr Surg. 2024;154(5):895e–905e. doi:10.1097/PRS.0000000000011335

13. Lai YW, Wu SH, Chou PR, et al. Autologous fat grafting in female genital area improves sexual function by increasing collagenesis, angiogenesis, and estrogen receptors. Aesthet Surg J. 2023;43(8):872–884. doi:10.1093/asj/sjad040

14. Strong AL, Cederna PS, Rubin JP, Coleman SR, Levi B. The current state of fat grafting: a review of harvesting, processing, and injection techniques. Plast Reconstr Surg. 2015;136(4):897–912. doi:10.1097/PRS.0000000000001590

15. Gutierrez-Ontalvilla P, Giner F, Vidal L, Iborra M. The effect of lipofilling and platelet-rich plasma on patients with moderate-severe vulvar lichen sclerosus who were non-responders to topical clobetasol propionate: a randomized pilot study. Aesthet Plast Surg. 2022;46(5):2469–2479. doi:10.1007/s00266-021-02718-1

16. Casarotti G, Tremolada C. A new treatment of genito-urinary post-menopausal atrophy with autologous micro-fragmented fat tissue: a thirty-six months follow-up case series. Eur Rev Med Pharmacol Sci. 2020;24(13):7420–7426. doi:10.26355/eurrev_202007_21910

17. Mantovani M, Gennai A, Russo PR. A new approach to regenerative medicine in gynecology. Int J Gynaecol Obstet. 2022;157(3):536–543. doi:10.1002/ijgo.13906

18. Moccia F, Pentangelo P, Ceccaroni A, et al. Injection treatments for vulvovaginal atrophy of menopause: a systematic review. Aesthet Plast Surg. 2023;47(6):2788–2799. doi:10.1007/s00266-023-03550-5

19. Gutierrez-Ontalvilla P, Gomez Rojas A, Iborra Colomino M, et al. Clinical and histopathological investigation of stromal vascular fraction and nanofat in vulvar lichen sclerosus. Aesthet Surg J. 2025;sjaf148. doi:10.1093/asj/sjaf148

20. Tedesco M, Bellei B, Garelli V, et al. Adipose tissue stromal vascular fraction and adipose tissue stromal vascular fraction plus platelet-rich plasma grafting: new regenerative perspectives in genital lichen sclerosus. Dermatol Ther. 2020;33(6):e14277. doi:10.1111/dth.14277

21. Borobia Pérez AI, Estévez Espejo JJ, Jiménez-González M, García López RD. Vulvovaginal collagen injection as a regenerative strategy in genitourinary syndrome of menopause: results of a pilot study. J Clin Med. 2026;15(4):1408. doi:10.3390/jcm15041408

22. Cihantimur B, Aglamis O, Ozsular Y. 360 genital fat transfer. Aesthet Plast Surg. 2021;45(6):2996–3002. doi:10.1007/s00266-021-02488-w

23. Kaur S, Rubin JP, Gusenoff J, et al. The General Registry of Autologous Fat Transfer: concept, design, and analysis of fat grafting complications. Plast Reconstr Surg. 2022;149(6):1118e–1129e. doi:10.1097/PRS.0000000000009162

24. Zheng Z, Yin J, Cheng B, Huang W. Materials selection for the injection into vaginal wall for treatment of vaginal atrophy. Aesthet Plast Surg. 2021;45(3):1231–1241. doi:10.1007/s00266-020-02054-w